PUBLISHER: Stratistics Market Research Consulting | PRODUCT CODE: 1250776
PUBLISHER: Stratistics Market Research Consulting | PRODUCT CODE: 1250776
Opioid Use Disorder Market Forecasts to 2028 - Global Analysis By Drug Class, Distribution Channel, Route of Administration, Age group, and By Geography
According to Stratistics MRC, the Global Opioid Use Disorder (OUD) Market is accounted for $3.17 billion in 2022 and is expected to reach $6.79 billion by 2028 growing at a CAGR of 13.5% during the forecast period. Opioids are a class of medications that also relax muscles, lessen pain, and ease stress. To treat moderate to severe pain, doctors often prescribe drugs like hydrocodone, oxycodone, codeine, fentanyl, methadone, morphine, and other prescription opioids. It involves functional alterations to brain circuits associated to motivation, stress, self-control, and decision-making, and because those changes may persist for a long time after drug use has stopped, it is recognised as a brain condition.
Market Dynamics:
Driver:
Growing focus of government & non-government institutions to support expansion
The expansion of the business is being fuelled in part by the growing involvement of governmental and non-governmental organisations in raising awareness of opioid overdose and associated consequences. Several groups have expanded their efforts to combat the issue as a result of the sharp rise in the number of opioid addicts. In order to help patients and decrease the effects of opioid dependence, many countries have increased their efforts. For instance, Health and Human Services (HHS) announced financing for substance use treatment and prevention programmes in order to increase access to medication-assisted treatment for opioid use disorder and curb prescription drug abuse. It is predicted that similar programmes would motivate more people with opioid-related problems to seek treatment.
Restraint:
Adverse effects of OUD drugs
The market is expected to experience challenges throughout the forecast period due to the negative effects of the medications used to treat opioid addiction. These medications frequently cause muscle aches, nausea, vomiting, diarrhoea, bone or joint pain, respiratory problems, bladder pain, constipation, and cramping in the abdomen. In addition, in extreme instances of a medication reaction, the patient may also experience depression and other psychological issues. The U.S. FDA issued a warning due to the hazards involved with these medications, which has a negative effect on the drug class and decreases the use of medications for this type of treatment.
Opportunity:
Increasing consideration of buprenorphine patches
An increase in demand for buprenorphine patch treatments has lately been observed in the market. These patches are regarded as an effective medication for the treatment of opioid use disorders. Transdermal patches have a number of traditional, self-administered benefits, including an easier drug administration mechanism and less pain. Also, these transdermal patches might be a viable substitute for patients who need 24/7 opioid medication for opioid use disorder. Also, it is predicted that during the forecast period, a growing number of new patients will contribute to the growth of the global market for opioid use disorder (OUD).
Threat:
Effects withdrawal syndrome
Withdrawal syndrome, which develops when repeated exposure to a pharmaceutical stimulus is stopped, is linked to dependency. Patients should be warned not to stop using long-term opioids without first lowering their dosage. Substance use disorder's subcategory of dependency can show physical, psychological, or both signs and symptoms. Regardless of the type of opioid used, withdrawal symptoms usually begin around the time of dependence. The main issue with opioid use disorder is withdrawal. When compared to methadone, withdrawal from heroin might start as quickly as five hours following the last dose. Withdrawal symptoms that last for days or weeks are referred to as prolonged abstinence syndrome.
Covid-19 Impact
Due to demand, the coronavirus pandemic has a variety of effects on the pharmaceutical business, ranging from favourable to unfavourable. Because fewer people are visiting healthcare institutions like hospitals and clinics, there has been a detrimental effect on the demand for some medications. Furthermore, a handful of governments have implemented a rigorous nationwide lockdown in an effort to reduce the number of coronavirus cases. This has caused the flow of patients between hospital settings to drastically decrease. Moreover, the cancellation or delay of unnecessary medical treatments has had a detrimental effect on market expansion. However, throughout the pandemic, well-known companies operating in the market for opioid use disorders, including Indivior PLC, saw a general reduction in their product revenues. As a result of COVID-19-related disruptions including lockdowns, transportation problems, and others, sales have fallen down quickly. Thus, it is anticipated that the market for opioid use disorders will suffer a setback.
The buprenorphine segment is expected to be the largest during the forecast period
The buprenorphine segment is estimated to have a lucrative growth. The most frequently recommended medications for OUD are buprenorphine/naloxone sublingual pills, buprenorphine sublingual tablets, and brand-name Suboxone. Because to its outstanding clinical profile, Suboxone Film is the medication that doctors most frequently prescribe in the OUD market. The high acceptance of this medicine can be due to a number of variables, including its good formulary coverage, high efficacy in controlling addiction, low potential for abuse, and very minor adverse effects.
The parenteral segment is expected to have the highest CAGR during the forecast period
The parenteral segment is anticipated to witness the fastest CAGR growth during the forecast period, due to the availability of several OUD medications in parenteral form and a range of dosages. As a result, this method of drug administration continues to rule the world market.
Region with highest share:
Asia Pacific is projected to hold the largest market share during the forecast period owing to increasing awareness amongst the general population regarding OUD. Additionally, the substantial patient population base and the increasing healthcare spending in the region are likely to favour the growth of the market in the region.
Region with highest CAGR:
North America is projected to have the highest CAGR over the forecast period. One of the major drivers behind North America's largest market share is the opioid epidemic that has ravaged the United States and Canada due to the governments are implementing a number of initiatives. For instance, the American government started a public awareness campaign to fight opioid addiction. Throughout the course of the projected year, new medications are also anticipated to enter the U.S. market, including Braeburn's CAM-2038-additional buprenorphine subcutaneous formulation for regular monthly injection.
Key Players in the market
Some of the key players profiled in the Opioid Use Disorder (OUD) Market include Alkermes, Titan Pharmaceuticals, Inc, Hikma Pharmaceuticals PLC, Indivior PLC, Mallinckrodt Pharmaceuticals, Camurus, Orexo AB, Viatris Inc, BioDelivery Sciences International Inc., Teva Pharmaceuticals Usa, Inc, Mylan, Azanta, Braeburn, Chiesi Pharmaceuticals, DiaMo Narcotics, MaynePharma Group, Knight Therapeutics, Dr. Reddy's Laboratories, Collegium Pharmaceutical, Inc and Buvidal.
Key Developments:
In March 2022, Collegium Pharmaceutical, Inc. announced that it had completed the acquisition of BioDelivery Sciences International Inc.
In June 2020, Titan Pharmaceuticals, Inc. entered into a partnership with Indegene to establish a multichannel digital marketing program throughout the U.S. and further increase their competence in providing Probuphine implant 2016 for opioid addiction patients.
In February 2021, Orexo AB announced its collaboration with ApexB.io and Magellan Rx Management to further research the use of Modia. This product is a digital therapeutic designed for patients with Opioid Use Disorder.
In December 2020, Orexo AB entered into an exclusive agreement with Accord Healthcare for the commercialization of ZUBSOLV and naloxone sublingual tablets in Europe.
In February 2019, Dr. Reddy's Laboratories announced the re-launch of its buprenorphine and naloxone sublingual film after the company received a favourable ruling in patent litigation.
Drug Classes Covered:
- Methadone
- Naltrexone
- Buprenorphine
Distribution Channels Covered:
- Retail Pharmacies & Stores
- Hospitals Pharmacies
- Online Pharmacies
Route of Administrations Covered:
- Parenteral
- Oral
Age groups Covered:
- 19 to 39
- 40 to 59
- Age 60 and over
Regions Covered:
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- UK
- Italy
- France
- Spain
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Australia
- New Zealand
- South Korea
- Rest of Asia Pacific
- South America
- Argentina
- Brazil
- Chile
- Rest of South America
- Middle East & Africa
- Saudi Arabia
- UAE
- Qatar
- South Africa
- Rest of Middle East & Africa
What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2020, 2021, 2022, 2025, and 2028
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
- Company Profiling
- Comprehensive profiling of additional market players (up to 3)
- SWOT Analysis of key players (up to 3)
- Regional Segmentation
- Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
- Competitive Benchmarking
- Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances
Table of Contents
1 Executive Summary
2 Preface
- 2.1 Abstract
- 2.2 Stake Holders
- 2.3 Research Scope
- 2.4 Research Methodology
- 2.4.1 Data Mining
- 2.4.2 Data Analysis
- 2.4.3 Data Validation
- 2.4.4 Research Approach
- 2.5 Research Sources
- 2.5.1 Primary Research Sources
- 2.5.2 Secondary Research Sources
- 2.5.3 Assumptions
3 Market Trend Analysis
- 3.1 Introduction
- 3.2 Drivers
- 3.3 Restraints
- 3.4 Opportunities
- 3.5 Threats
- 3.6 Emerging Markets
- 3.7 Impact of Covid-19
4 Porters Five Force Analysis
- 4.1 Bargaining power of suppliers
- 4.2 Bargaining power of buyers
- 4.3 Threat of substitutes
- 4.4 Threat of new entrants
- 4.5 Competitive rivalry
5 Global Opioid Use Disorder (OUD) Market, By Drug Class
- 5.1 Introduction
- 5.2 Methadone
- 5.3 Naltrexone
- 5.4 Buprenorphine
- 5.4.1 Bunavail
- 5.4.2 Sublocade
- 5.4.3 Suboxone
- 5.4.4 Zubsolv
6 Global Opioid Use Disorder (OUD) Market, By Distribution Channel
- 6.1 Introduction
- 6.2 Retail Pharmacies & Stores
- 6.3 Hospitals Pharmacies
- 6.4 Online Pharmacies
7 Global Opioid Use Disorder (OUD) Market, By Route of Administration
- 7.1 Introduction
- 7.2 Parenteral
- 7.3 Oral
8 Global Opioid Use Disorder (OUD) Market, By Age group
- 8.1 Introduction
- 8.2 19 to 39
- 8.3 40 to 59
- 8.4 Age 60 and over
9 Global Opioid Use Disorder (OUD) Market, By Geography
- 9.1 Introduction
- 9.2 North America
- 9.2.1 US
- 9.2.2 Canada
- 9.2.3 Mexico
- 9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 Italy
- 9.3.4 France
- 9.3.5 Spain
- 9.3.6 Rest of Europe
- 9.4 Asia Pacific
- 9.4.1 Japan
- 9.4.2 China
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 New Zealand
- 9.4.6 South Korea
- 9.4.7 Rest of Asia Pacific
- 9.5 South America
- 9.5.1 Argentina
- 9.5.2 Brazil
- 9.5.3 Chile
- 9.5.4 Rest of South America
- 9.6 Middle East & Africa
- 9.6.1 Saudi Arabia
- 9.6.2 UAE
- 9.6.3 Qatar
- 9.6.4 South Africa
- 9.6.5 Rest of Middle East & Africa
10 Key Developments
- 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
- 10.2 Acquisitions & Mergers
- 10.3 New Product Launch
- 10.4 Expansions
- 10.5 Other Key Strategies
11 Company Profiling
- 11.1 Alkermes
- 11.2 Titan Pharmaceuticals, Inc
- 11.3 Hikma Pharmaceuticals PLC
- 11.4 Indivior PLC
- 11.5 Mallinckrodt Pharmaceuticals
- 11.6 Camurus
- 11.7 Orexo AB
- 11.8 Viatris Inc
- 11.9 BioDelivery Sciences International Inc.
- 11.10 Teva Pharmaceuticals Usa, Inc
- 11.11 Mylan
- 11.12 Azanta
- 11.13 Braeburn
- 11.14 Chiesi Pharmaceuticals
- 11.15 DiaMo Narcotics
- 11.16 MaynePharma Group
- 11.17 Knight Therapeutics
- 11.18 Dr. Reddy's Laboratories
- 11.19 Collegium Pharmaceutical, Inc
- 11.20 Buvidal
List of Tables
- Table 1 Global Opioid Use Disorder (OUD) Market Outlook, By Region (2020-2028) ($MN)
- Table 2 Global Opioid Use Disorder (OUD) Market Outlook, By Drug Class (2020-2028) ($MN)
- Table 3 Global Opioid Use Disorder (OUD) Market Outlook, By Methadone (2020-2028) ($MN)
- Table 4 Global Opioid Use Disorder (OUD) Market Outlook, By Naltrexone (2020-2028) ($MN)
- Table 5 Global Opioid Use Disorder (OUD) Market Outlook, By Buprenorphine (2020-2028) ($MN)
- Table 6 Global Opioid Use Disorder (OUD) Market Outlook, By Bunavail (2020-2028) ($MN)
- Table 7 Global Opioid Use Disorder (OUD) Market Outlook, By Sublocade (2020-2028) ($MN)
- Table 8 Global Opioid Use Disorder (OUD) Market Outlook, By Suboxone (2020-2028) ($MN)
- Table 9 Global Opioid Use Disorder (OUD) Market Outlook, By Zubsolv (2020-2028) ($MN)
- Table 10 Global Opioid Use Disorder (OUD) Market Outlook, By Distribution Channel (2020-2028) ($MN)
- Table 11 Global Opioid Use Disorder (OUD) Market Outlook, By Retail Pharmacies & Stores (2020-2028) ($MN)
- Table 12 Global Opioid Use Disorder (OUD) Market Outlook, By Hospitals Pharmacies (2020-2028) ($MN)
- Table 13 Global Opioid Use Disorder (OUD) Market Outlook, By Online Pharmacies (2020-2028) ($MN)
- Table 14 Global Opioid Use Disorder (OUD) Market Outlook, By Route of Administration (2020-2028) ($MN)
- Table 15 Global Opioid Use Disorder (OUD) Market Outlook, By Parenteral (2020-2028) ($MN)
- Table 16 Global Opioid Use Disorder (OUD) Market Outlook, By Oral (2020-2028) ($MN)
- Table 17 Global Opioid Use Disorder (OUD) Market Outlook, By Age group (2020-2028) ($MN)
- Table 18 Global Opioid Use Disorder (OUD) Market Outlook, By 19 to 39 (2020-2028) ($MN)
- Table 19 Global Opioid Use Disorder (OUD) Market Outlook, By 40 to 59 (2020-2028) ($MN)
- Table 20 Global Opioid Use Disorder (OUD) Market Outlook, By Age 60 and over (2020-2028) ($MN)
- Table 21 North America Opioid Use Disorder (OUD) Market Outlook, By Country (2020-2028) ($MN)
- Table 22 North America Opioid Use Disorder (OUD) Market Outlook, By Drug Class (2020-2028) ($MN)
- Table 23 North America Opioid Use Disorder (OUD) Market Outlook, By Methadone (2020-2028) ($MN)
- Table 24 North America Opioid Use Disorder (OUD) Market Outlook, By Naltrexone (2020-2028) ($MN)
- Table 25 North America Opioid Use Disorder (OUD) Market Outlook, By Buprenorphine (2020-2028) ($MN)
- Table 26 North America Opioid Use Disorder (OUD) Market Outlook, By Bunavail (2020-2028) ($MN)
- Table 27 North America Opioid Use Disorder (OUD) Market Outlook, By Sublocade (2020-2028) ($MN)
- Table 28 North America Opioid Use Disorder (OUD) Market Outlook, By Suboxone (2020-2028) ($MN)
- Table 29 North America Opioid Use Disorder (OUD) Market Outlook, By Zubsolv (2020-2028) ($MN)
- Table 30 North America Opioid Use Disorder (OUD) Market Outlook, By Distribution Channel (2020-2028) ($MN)
- Table 31 North America Opioid Use Disorder (OUD) Market Outlook, By Retail Pharmacies & Stores (2020-2028) ($MN)
- Table 32 North America Opioid Use Disorder (OUD) Market Outlook, By Hospitals Pharmacies (2020-2028) ($MN)
- Table 33 North America Opioid Use Disorder (OUD) Market Outlook, By Online Pharmacies (2020-2028) ($MN)
- Table 34 North America Opioid Use Disorder (OUD) Market Outlook, By Route of Administration (2020-2028) ($MN)
- Table 35 North America Opioid Use Disorder (OUD) Market Outlook, By Parenteral (2020-2028) ($MN)
- Table 36 North America Opioid Use Disorder (OUD) Market Outlook, By Oral (2020-2028) ($MN)
- Table 37 North America Opioid Use Disorder (OUD) Market Outlook, By Age group (2020-2028) ($MN)
- Table 38 North America Opioid Use Disorder (OUD) Market Outlook, By 19 to 39 (2020-2028) ($MN)
- Table 39 North America Opioid Use Disorder (OUD) Market Outlook, By 40 to 59 (2020-2028) ($MN)
- Table 40 North America Opioid Use Disorder (OUD) Market Outlook, By Age 60 and over (2020-2028) ($MN)
- Table 41 Europe Opioid Use Disorder (OUD) Market Outlook, By Country (2020-2028) ($MN)
- Table 42 Europe Opioid Use Disorder (OUD) Market Outlook, By Drug Class (2020-2028) ($MN)
- Table 43 Europe Opioid Use Disorder (OUD) Market Outlook, By Methadone (2020-2028) ($MN)
- Table 44 Europe Opioid Use Disorder (OUD) Market Outlook, By Naltrexone (2020-2028) ($MN)
- Table 45 Europe Opioid Use Disorder (OUD) Market Outlook, By Buprenorphine (2020-2028) ($MN)
- Table 46 Europe Opioid Use Disorder (OUD) Market Outlook, By Bunavail (2020-2028) ($MN)
- Table 47 Europe Opioid Use Disorder (OUD) Market Outlook, By Sublocade (2020-2028) ($MN)
- Table 48 Europe Opioid Use Disorder (OUD) Market Outlook, By Suboxone (2020-2028) ($MN)
- Table 49 Europe Opioid Use Disorder (OUD) Market Outlook, By Zubsolv (2020-2028) ($MN)
- Table 50 Europe Opioid Use Disorder (OUD) Market Outlook, By Distribution Channel (2020-2028) ($MN)
- Table 51 Europe Opioid Use Disorder (OUD) Market Outlook, By Retail Pharmacies & Stores (2020-2028) ($MN)
- Table 52 Europe Opioid Use Disorder (OUD) Market Outlook, By Hospitals Pharmacies (2020-2028) ($MN)
- Table 53 Europe Opioid Use Disorder (OUD) Market Outlook, By Online Pharmacies (2020-2028) ($MN)
- Table 54 Europe Opioid Use Disorder (OUD) Market Outlook, By Route of Administration (2020-2028) ($MN)
- Table 55 Europe Opioid Use Disorder (OUD) Market Outlook, By Parenteral (2020-2028) ($MN)
- Table 56 Europe Opioid Use Disorder (OUD) Market Outlook, By Oral (2020-2028) ($MN)
- Table 57 Europe Opioid Use Disorder (OUD) Market Outlook, By Age group (2020-2028) ($MN)
- Table 58 Europe Opioid Use Disorder (OUD) Market Outlook, By 19 to 39 (2020-2028) ($MN)
- Table 59 Europe Opioid Use Disorder (OUD) Market Outlook, By 40 to 59 (2020-2028) ($MN)
- Table 60 Europe Opioid Use Disorder (OUD) Market Outlook, By Age 60 and over (2020-2028) ($MN)
- Table 61 Asia Pacific Opioid Use Disorder (OUD) Market Outlook, By Country (2020-2028) ($MN)
- Table 62 Asia Pacific Opioid Use Disorder (OUD) Market Outlook, By Drug Class (2020-2028) ($MN)
- Table 63 Asia Pacific Opioid Use Disorder (OUD) Market Outlook, By Methadone (2020-2028) ($MN)
- Table 64 Asia Pacific Opioid Use Disorder (OUD) Market Outlook, By Naltrexone (2020-2028) ($MN)
- Table 65 Asia Pacific Opioid Use Disorder (OUD) Market Outlook, By Buprenorphine (2020-2028) ($MN)
- Table 66 Asia Pacific Opioid Use Disorder (OUD) Market Outlook, By Bunavail (2020-2028) ($MN)
- Table 67 Asia Pacific Opioid Use Disorder (OUD) Market Outlook, By Sublocade (2020-2028) ($MN)
- Table 68 Asia Pacific Opioid Use Disorder (OUD) Market Outlook, By Suboxone (2020-2028) ($MN)
- Table 69 Asia Pacific Opioid Use Disorder (OUD) Market Outlook, By Zubsolv (2020-2028) ($MN)
- Table 70 Asia Pacific Opioid Use Disorder (OUD) Market Outlook, By Distribution Channel (2020-2028) ($MN)
- Table 71 Asia Pacific Opioid Use Disorder (OUD) Market Outlook, By Retail Pharmacies & Stores (2020-2028) ($MN)
- Table 72 Asia Pacific Opioid Use Disorder (OUD) Market Outlook, By Hospitals Pharmacies (2020-2028) ($MN)
- Table 73 Asia Pacific Opioid Use Disorder (OUD) Market Outlook, By Online Pharmacies (2020-2028) ($MN)
- Table 74 Asia Pacific Opioid Use Disorder (OUD) Market Outlook, By Route of Administration (2020-2028) ($MN)
- Table 75 Asia Pacific Opioid Use Disorder (OUD) Market Outlook, By Parenteral (2020-2028) ($MN)
- Table 76 Asia Pacific Opioid Use Disorder (OUD) Market Outlook, By Oral (2020-2028) ($MN)
- Table 77 Asia Pacific Opioid Use Disorder (OUD) Market Outlook, By Age group (2020-2028) ($MN)
- Table 78 Asia Pacific Opioid Use Disorder (OUD) Market Outlook, By 19 to 39 (2020-2028) ($MN)
- Table 79 Asia Pacific Opioid Use Disorder (OUD) Market Outlook, By 40 to 59 (2020-2028) ($MN)
- Table 80 Asia Pacific Opioid Use Disorder (OUD) Market Outlook, By Age 60 and over (2020-2028) ($MN)
- Table 81 South America Opioid Use Disorder (OUD) Market Outlook, By Country (2020-2028) ($MN)
- Table 82 South America Opioid Use Disorder (OUD) Market Outlook, By Drug Class (2020-2028) ($MN)
- Table 83 South America Opioid Use Disorder (OUD) Market Outlook, By Methadone (2020-2028) ($MN)
- Table 84 South America Opioid Use Disorder (OUD) Market Outlook, By Naltrexone (2020-2028) ($MN)
- Table 85 South America Opioid Use Disorder (OUD) Market Outlook, By Buprenorphine (2020-2028) ($MN)
- Table 86 South America Opioid Use Disorder (OUD) Market Outlook, By Bunavail (2020-2028) ($MN)
- Table 87 South America Opioid Use Disorder (OUD) Market Outlook, By Sublocade (2020-2028) ($MN)
- Table 88 South America Opioid Use Disorder (OUD) Market Outlook, By Suboxone (2020-2028) ($MN)
- Table 89 South America Opioid Use Disorder (OUD) Market Outlook, By Zubsolv (2020-2028) ($MN)
- Table 90 South America Opioid Use Disorder (OUD) Market Outlook, By Distribution Channel (2020-2028) ($MN)
- Table 91 South America Opioid Use Disorder (OUD) Market Outlook, By Retail Pharmacies & Stores (2020-2028) ($MN)
- Table 92 South America Opioid Use Disorder (OUD) Market Outlook, By Hospitals Pharmacies (2020-2028) ($MN)
- Table 93 South America Opioid Use Disorder (OUD) Market Outlook, By Online Pharmacies (2020-2028) ($MN)
- Table 94 South America Opioid Use Disorder (OUD) Market Outlook, By Route of Administration (2020-2028) ($MN)
- Table 95 South America Opioid Use Disorder (OUD) Market Outlook, By Parenteral (2020-2028) ($MN)
- Table 96 South America Opioid Use Disorder (OUD) Market Outlook, By Oral (2020-2028) ($MN)
- Table 97 South America Opioid Use Disorder (OUD) Market Outlook, By Age group (2020-2028) ($MN)
- Table 98 South America Opioid Use Disorder (OUD) Market Outlook, By 19 to 39 (2020-2028) ($MN)
- Table 99 South America Opioid Use Disorder (OUD) Market Outlook, By 40 to 59 (2020-2028) ($MN)
- Table 100 South America Opioid Use Disorder (OUD) Market Outlook, By Age 60 and over (2020-2028) ($MN)
- Table 101 Middle East & Africa Opioid Use Disorder (OUD) Market Outlook, By Country (2020-2028) ($MN)
- Table 102 Middle East & Africa Opioid Use Disorder (OUD) Market Outlook, By Drug Class (2020-2028) ($MN)
- Table 103 Middle East & Africa Opioid Use Disorder (OUD) Market Outlook, By Methadone (2020-2028) ($MN)
- Table 104 Middle East & Africa Opioid Use Disorder (OUD) Market Outlook, By Naltrexone (2020-2028) ($MN)
- Table 105 Middle East & Africa Opioid Use Disorder (OUD) Market Outlook, By Buprenorphine (2020-2028) ($MN)
- Table 106 Middle East & Africa Opioid Use Disorder (OUD) Market Outlook, By Bunavail (2020-2028) ($MN)
- Table 107 Middle East & Africa Opioid Use Disorder (OUD) Market Outlook, By Sublocade (2020-2028) ($MN)
- Table 108 Middle East & Africa Opioid Use Disorder (OUD) Market Outlook, By Suboxone (2020-2028) ($MN)
- Table 109 Middle East & Africa Opioid Use Disorder (OUD) Market Outlook, By Zubsolv (2020-2028) ($MN)
- Table 110 Middle East & Africa Opioid Use Disorder (OUD) Market Outlook, By Distribution Channel (2020-2028) ($MN)
- Table 111 Middle East & Africa Opioid Use Disorder (OUD) Market Outlook, By Retail Pharmacies & Stores (2020-2028) ($MN)
- Table 112 Middle East & Africa Opioid Use Disorder (OUD) Market Outlook, By Hospitals Pharmacies (2020-2028) ($MN)
- Table 113 Middle East & Africa Opioid Use Disorder (OUD) Market Outlook, By Online Pharmacies (2020-2028) ($MN)
- Table 114 Middle East & Africa Opioid Use Disorder (OUD) Market Outlook, By Route of Administration (2020-2028) ($MN)
- Table 115 Middle East & Africa Opioid Use Disorder (OUD) Market Outlook, By Parenteral (2020-2028) ($MN)
- Table 116 Middle East & Africa Opioid Use Disorder (OUD) Market Outlook, By Oral (2020-2028) ($MN)
- Table 117 Middle East & Africa Opioid Use Disorder (OUD) Market Outlook, By Age group (2020-2028) ($MN)
- Table 118 Middle East & Africa Opioid Use Disorder (OUD) Market Outlook, By 19 to 39 (2020-2028) ($MN)
- Table 119 Middle East & Africa Opioid Use Disorder (OUD) Market Outlook, By 40 to 59 (2020-2028) ($MN)
- Table 120 Middle East & Africa Opioid Use Disorder (OUD) Market Outlook, By Age 60 and over (2020-2028) ($MN)
